Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

75.39 +1.30 (+1.75%)
Streaming Delayed Price Updated: 2:03 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 282,943
Open 74.23
Bid (Size) 75.35 (200)
Ask (Size) 75.46 (300)
Prev. Close 74.10
Today's Range 73.96 - 75.67
52wk Range 35.95 - 87.50
Shares Outstanding 79,931,766
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Reasonable Valuation ↗
PTC Therapeutics offers high growth at a fair price, with strong earnings and revenue increases, trading below industry valuations. 
Via Chartmill
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+64.3%
+64.3%
1 Month
+4.0%
+4.0%
3 Month
+29.3%
+29.3%
6 Month
+48.4%
+48.4%
1 Year
+50.8%
+50.8%

More News

Read More
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You? ↗
Via The Motley Fool
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake? ↗
Via The Motley Fool
News headline image
A PTC Therapeutics (PTCT) Insider Sold 10,000 Shares for $795,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
Via Chartmill
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
Via The Motley Fool
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows Strong Growth Momentum and Technical Health ↗
Via Chartmill
News headline image
Sarepta Therapeutics Shares Plummet as Key DMD Treatments Miss Primary Endpoint in Late-Stage Trial
Via MarketMinute
Topics Death
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Mix of Strong Growth and Bullish Technical Setup ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents an Affordable Growth Opportunity ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Presents a Compelling Case for Affordable Growth Investing ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Combines Strong Growth with Bullish Technical Setup ↗
Via Chartmill
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech ↗
Via Chartmill
News headline image
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
Via Benzinga
News headline image
Here's Why Shares in PTC Therapeutics Soared This Week ↗
Via The Motley Fool
News headline image
PTC Therapeutics Stock Is Stuck In A Multi-Year Slump ↗
Via Benzinga
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock ↗
Via Chartmill
PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided ↗
Via Stocktwits
News headline image
PTC Therapeutics Faces FDA Rejection On Rare Disease Treatment Over Efficacy Concerns ↗
Via Benzinga

Frequently Asked Questions

Is PTC Therapeutics, Inc. - Common Stock publicly traded?
Yes, PTC Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does PTC Therapeutics, Inc. - Common Stock trade on?
PTC Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for PTC Therapeutics, Inc. - Common Stock?
The ticker symbol for PTC Therapeutics, Inc. - Common Stock is PTCT on the Nasdaq Stock Market
What is the current price of PTC Therapeutics, Inc. - Common Stock?
The current price of PTC Therapeutics, Inc. - Common Stock is 75.39
When was PTC Therapeutics, Inc. - Common Stock last traded?
The last trade of PTC Therapeutics, Inc. - Common Stock was at 12/11/25 02:03 PM ET
What is the market capitalization of PTC Therapeutics, Inc. - Common Stock?
The market capitalization of PTC Therapeutics, Inc. - Common Stock is 6.03B
How many shares of PTC Therapeutics, Inc. - Common Stock are outstanding?
PTC Therapeutics, Inc. - Common Stock has 6B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS